Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

High mutational load gets a response Cancers harbor many genetic mutations. Defects in DNA mismatch repair prevent tumors from repairing certain types of DNA damage and lead to a hypermutable genomic state known as microsatellite instability (MSI). Some tumors with a high degree of MSI may be treatable with PD-1 (programmed cell death–1) immunotherapy, but patient response is highly variable. Mandal et al. studied drivers of differential response to immunotherapy in these patients and found that MSI intensity and insertion-deletion mutations strongly affected therapeutic outcome. Science, this issue p. 485 Effective PD-1 immunotherapy is influenced by the intensity of tumor microsatellite instability. Tumors with mismatch repair deficiency (MMR-d) are characterized by sequence alterations in microsatellites and can accumulate thousands of mutations. This high mutational burden renders tumors immunogenic and sensitive to programmed cell death–1 (PD-1) immune checkpoint inhibitors. Yet, despite their tumor immunogenicity, patients with MMR-deficient tumors experience highly variable responses, and roughly half are refractory to treatment. We present experimental and clinical evidence showing that the degree of microsatellite instability (MSI) and resultant mutational load, in part, underlies the variable response to PD-1 blockade immunotherapy in MMR-d human and mouse tumors. The extent of response is particularly associated with the accumulation of insertion-deletion (indel) mutational load. This study provides a rationale for the genome-wide characterization of MSI intensity and mutational load to better profile responses to anti–PD-1 immunotherapy across MMR-deficient human cancers.

[1]  Peter J. Park,et al.  The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes , 2013, Cell.

[2]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.

[3]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[4]  Colin C Pritchard,et al.  Microsatellite instability detection by next generation sequencing. , 2014, Clinical chemistry.

[5]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[6]  M. Kohonen-Corish,et al.  Low microsatellite instability is associated with poor prognosis in stage C colon cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[8]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[9]  F. Nicolantonio,et al.  Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth , 2017, Nature.

[10]  D. Tu,et al.  Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer , 2020, JAMA oncology.

[11]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[12]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[13]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[14]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[15]  Nicolai J. Birkbak,et al.  Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. , 2017, The Lancet. Oncology.

[16]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[17]  Ben Lehner,et al.  Differential DNA mismatch repair underlies mutation rate variation across the human genome , 2015, Nature.

[18]  J. Andrechak,et al.  Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function , 2020, Antibody therapeutics.

[19]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[20]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[21]  Nadeem Riaz,et al.  Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy , 2016, Nature Genetics.

[22]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[23]  J. Yeong,et al.  Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers , 2020, Frontiers in Oncology.

[24]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[25]  Ritika Kundra,et al.  Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. , 2018, Cancer cell.

[26]  David R. Jones,et al.  Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. , 2018, Cancer discovery.

[27]  Subbaya Subramanian,et al.  Acquired Resistance to Immune Checkpoint Blockade Therapies , 2020, Cancers.

[28]  S. Nik-Zainal,et al.  Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer , 2017, Science.

[29]  L. Ny,et al.  Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection , 2020, Case Reports in Oncology.

[30]  Ahmet Zehir,et al.  Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. , 2017, JCO precision oncology.